share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/12/02 13:22

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics has entered into a Securities Purchase Agreement with a single investor and CEO Alon Ben-Noon for a $5 million private placement at $1.25 per share, representing a 25% premium to market price. The offering includes 2.34M ordinary shares, 1.66M pre-funded warrants, and 8M ordinary warrants, with proceeds to be delivered in two tranches by March 2025.The company plans to use the proceeds to advance the clinical development of PrimeC for ALS, support research for Alzheimer's and Parkinson's disease treatments, and fund general corporate purposes. The ordinary warrants are exercisable immediately at $1.25 per share with a five-year term, while pre-funded warrants have a nominal exercise price of $0.0001.The private placement is being conducted under Section 4(a)(2) of the Securities Act exemption, with securities to be registered for resale through a Form F-3 registration statement. The transaction includes standard provisions limiting warrant holders to maximum ownership of 9.99% of outstanding shares after exercise.
NeuroSense Therapeutics has entered into a Securities Purchase Agreement with a single investor and CEO Alon Ben-Noon for a $5 million private placement at $1.25 per share, representing a 25% premium to market price. The offering includes 2.34M ordinary shares, 1.66M pre-funded warrants, and 8M ordinary warrants, with proceeds to be delivered in two tranches by March 2025.The company plans to use the proceeds to advance the clinical development of PrimeC for ALS, support research for Alzheimer's and Parkinson's disease treatments, and fund general corporate purposes. The ordinary warrants are exercisable immediately at $1.25 per share with a five-year term, while pre-funded warrants have a nominal exercise price of $0.0001.The private placement is being conducted under Section 4(a)(2) of the Securities Act exemption, with securities to be registered for resale through a Form F-3 registration statement. The transaction includes standard provisions limiting warrant holders to maximum ownership of 9.99% of outstanding shares after exercise.
NeuroSense Therapeutics與單一投資者及首席執行官Alon Ben-Noon簽署了一項證券購買協議，進行500萬美元的定向增發，發行價格爲每股1.25美元，較市場價格溢價25%。此次發行包括234萬普通股票、166萬預售認股權證和800萬普通認股權證，所得款項將在2025年3月之前分兩次交付。該公司計劃利用這些資金推進PrimeC用於肌萎縮側索硬化症(ALS)的臨牀開發，支持阿爾茨海默病和帕金森病治療的研究，以及用於一般公司事務的資金。普通認股權證可立即以每股1.25美元的價格行使，有效期爲五年，而預售認股權證的名義行權價爲0.0001美元。此次定向增發是在《證券法》第4(a)(2)條款的豁免下進行的，證券將通過Form F-3註冊聲明進行二次出售的註冊。該交易包括限制認股權證持有者在行使後對流通股的最大持有比例爲9.99%的標準條款。
NeuroSense Therapeutics與單一投資者及首席執行官Alon Ben-Noon簽署了一項證券購買協議，進行500萬美元的定向增發，發行價格爲每股1.25美元，較市場價格溢價25%。此次發行包括234萬普通股票、166萬預售認股權證和800萬普通認股權證，所得款項將在2025年3月之前分兩次交付。該公司計劃利用這些資金推進PrimeC用於肌萎縮側索硬化症(ALS)的臨牀開發，支持阿爾茨海默病和帕金森病治療的研究，以及用於一般公司事務的資金。普通認股權證可立即以每股1.25美元的價格行使，有效期爲五年，而預售認股權證的名義行權價爲0.0001美元。此次定向增發是在《證券法》第4(a)(2)條款的豁免下進行的，證券將通過Form F-3註冊聲明進行二次出售的註冊。該交易包括限制認股權證持有者在行使後對流通股的最大持有比例爲9.99%的標準條款。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Portage Biotech
    PRTG
    -- 9.600
    萊斯康製藥
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點